Reset Form | Print Form

New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form

Elevidys (delandistrogene moxeparvovec-rokl)

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

FIRST NAME:

MEDICAID ID NUMBER:

DATE OF BIRTH: – –

GENDER: ☐ Male ☐ Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

SECTION II: PRESCRIBER INFORMATION

LAST NAME:

FIRST NAME:

SPECIALTY:

NPI NUMBER:

PHONE NUMBER: – –

FAX NUMBER: – –

SECTION III: CLINICAL HISTORY

1. Does the patient have Duchenne Muscular Dystrophy (DMD) without a confirmed deletion in exons 8 and/or 9? ☐ Yes ☐ No
2. Is the patient's baseline anti-AArh74 total binding antibody titer < 1:400? ☐ Yes ☐ No
3. Is the patient ambulatory? ☐ Yes ☐ No

   North Star Ambulatory Assessment score: _____
4. Will the patient also receive DMD-directed antisense oligonucleotides during treatment with Elevidys (e.g. golodirsen, viltolarsen)? ☐ Yes ☐ No
5. If the patient is currently receiving treatment with a DMD-directed antisense oligonucleotides, will therapy be discontinued at least 7 days prior to Elevidys? ☐ Yes ☐ No
6. Will the patient start or continue to use a corticosteroid? ☐ Yes ☐ No

   a. Regimen and start date: _____

(Form continued on next page.)

Fax to DHHS; medication is administered in inpatient setting:
Phone: 1-603-271-9384
Fax: 1-603-314-8101

Review Date: 01/29/2024

Magellan Rx MANAGEMENT℠

New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form
Elevidys (delandistrogene moxeparvovec-rokl)

PATIENT LAST NAME:

PATIENT FIRST NAME:

SECTION III: CLINICAL HISTORY

7. Does the patient have an active infection? ☐ Yes ☐ No
8. Will the troponin-1 level be assessed at baseline and after Elevidys dose according to a facility protocol? ☐ Yes ☐ No
9. Will the liver function be assessed at baseline and after Elevidys dose according to a facility protocol? ☐ Yes ☐ No
   a. Attach copy of baseline liver function tests.
10. Attach protocol for Elevidys monitoring.

Please provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____ **DATE**: _____

Facility where infusion to be provided: _____

Medicaid Provider Number of Facility: _____

Fax to DHHS; medication is administered in inpatient setting:
Phone: 1-603-271-9384
Fax: 1-603-314-8101

Magellan Rx MANAGEMENT